Worldwide, obesity is considered as an important public health problem. This study aims to explore the social and economic factors associated with overweight and obesity among women of childbearing age residing in the urban area of Morocco. This is a descriptive and analytical study conducted among women (N=240), aged between 15 and 49 years. At recruitment, socioeconomic status (SES) of each participant was assessed, anthropometric parameters were recorded, and body mass index (BMI), waist circumference, and waist-to-hip ratio (WHR) were measured to assess overweight and obesity. Data regarding skipped meals (breakfast, lunch, and dinner) were collected using an adapted questionnaire. The prevalence of overweight and obesity among women of childbearing age was 29.9% and 15.4%, respectively, while for abdominal obesity, the prevalence of overweight and obesity was, respectively, 39.9% and 60.1%. The results indicate that the prevalence of overweight and obesity among women is higher in women aged over 30. A significant association was shown between education level and both BMI and WHR (r1=−0.23, r2=−0.17, p < 0.05), respectively, and there is also a significant correlation between household size and WHR abdominal obesity (r=0.21, p=0.05). Our results reinforce the necessity to improve the access of all social classes in Morocco to reliable information on the determinants and consequences of obesity and to develop plans for adequate prevention and management of obesity.

Iodine is required for the production of the thyroid hormones essential for the growth and development of the brain. All forms of iodine deficiency (ID) affect the mental development of the child. Our study aims to assess the impact of ID on the intellectual development of Moroccan schoolchildren and to evaluate the effect of consumption of fortified milk on reducing ID. In a double-blind controlled trial conducted on schoolchildren, children were divided into two groups to receive fortified milk (30% of cover of RDI iodine) or nonfortified milk for 9 months. Urinary iodine was analyzed using the Sandell-Kolthoff reaction, a dynamic cognitive test using Raven's Standard Progressive Matrices to assess learning potential was performed at baseline and end line, and anthropometric assessment was done only at baseline. The study included schoolchildren who were severely iodine deficient. The prevalence of malnutrition was high in both groups; in this study, we found improvements in iodine status and in cognitive abilities among Moroccan schoolchildren. Our study showed that the consumption of fortified milk led to a clear improvement in iodine status and also appeared to have a favorable effect on the cognitive ability of Moroccan schoolchildren in a rural mountainous region.

Iron deficiency constitutes a major public health problem in Morocco, mainly among women and children. The aim of our paper is to assess the efficacy of consumption of multiple micronutrients (MMN) fortified milk on iron status of Moroccan schoolchildren living in rural region. Children (N = 195), aged 7 to 9 y, were recruited from schools and divided into two groups: the nonfortified group (NFG) received daily a nonfortified Ultra-High-Temperature (UHT) milk and the fortified group received (FG) daily UHT milk fortified with multiple micronutrients including iron sulfate. Blood samples were collected at baseline (T0) and after 9 months (T9). Hemoglobin (Hb) was measured in situ by Hemocue device; ferritin and C Reactive Protein were assessed in serum using ELISA and nephelometry techniques, respectively. Results were considered significant when the p value was <0.05. At T9 FG showed a reduction of iron deficiency from 50.9% to 37.2% (p = 0.037). Despite the low prevalence of iron deficiency anemia (1.9%); more than 50% of children in our sample suffered from iron deficiency at baseline. The consumption of fortified milk reduced the prevalence of iron deficiency by 27% in schoolchildren living in high altitude rural region of Morocco. Clinical Trial Registration. Our study is registered in the Pan African Clinical Trial Registry with the identification number PACTR201410000896410.